机译:中国癌症患者多肠素 - 环磷酰胺化疗的最佳当代抗预防性的鉴定:3次前瞻性研究后HOC分析
Department of Clinical Oncology Prince of Wales Hospital Faculty of Medicine Hong Kong Cancer Institute Hong Kong ChinaState Key Laboratory of Translational Oncology The Chinese University of Hong Kong Hong Kong China;
Department of Clinical Oncology Prince of Wales Hospital Faculty of Medicine Hong Kong Cancer Institute Hong Kong China;
Department of Clinical Oncology Prince of Wales Hospital Faculty of Medicine Hong Kong Cancer Institute Hong Kong China;
Department of Clinical Oncology Prince of Wales Hospital Faculty of Medicine Hong Kong Cancer Institute Hong Kong China;
Department of Clinical Oncology Prince of Wales Hospital Faculty of Medicine Hong Kong Cancer Institute Hong Kong China;
Department of Clinical Oncology Prince of Wales Hospital Faculty of Medicine Hong Kong Cancer Institute Hong Kong China;
Department of Clinical Oncology Prince of Wales Hospital Faculty of Medicine Hong Kong Cancer Institute Hong Kong China;
Department of Clinical Oncology Prince of Wales Hospital Faculty of Medicine Hong Kong Cancer Institute Hong Kong China;
Department of Clinical Oncology Prince of Wales Hospital Faculty of Medicine Hong Kong Cancer Institute Hong Kong China;
Department of Clinical Oncology Prince of Wales Hospital Faculty of Medicine Hong Kong Cancer Institute Hong Kong China;
Department of Clinical Oncology Princess Margaret Hospital Hong Kong China;
Department of Clinical Oncology Prince of Wales Hospital Faculty of Medicine Hong Kong Cancer Institute Hong Kong China;
Department of Clinical Oncology Prince of Wales Hospital Faculty of Medicine Hong Kong Cancer Institute Hong Kong ChinaState Key Laboratory of Translational Oncology The Chinese University of Hong Kong Hong Kong China;
Netupitant; palonosetron; aprepitant; olanzapine; NEPA; Asians;